Mastoscopic sentinel lymph node biopsy in breast cancer

• Autorzy: Boni Ding , Hongyan Zhang , Xiaorong Li , Liyuan Qian , Xuedong Chen , Wei Wu , Yanguang Wen , Yujun Zhao
• Języki publikacji: EN

Abstrakty

EN

Background: Previous studies have demonstrated that mastoscopic sentinel lymph node biopsy (MSLNB) has good identification rate (IR) and low false negative rate (FNR). However, few studies have directly compared the surgical performance and peri- and post-operative factors of MSLNB with conventional sentinel lymph node biopsy (SLNB). Methodology: Sixty patients diagnosed with breast cancer were recruited and randomly assigned to one of the three groups: MSLNB, SLNB and SLNB with lipolysis injection. Peri- and post-operative parameters were compared using general linear models. To examine the effect of age on these parameters, we performed separate analysis stratified by age (≤50 years old vs. >50 years old). Results: Patients in the MSLNB group experienced longer surgery and suffered higher surgical cost than patients who underwent conventional SLNB or SLNB with lipolysis injection (p<0.0001). Despite this, they had significantly less blood loss than those who underwent conventional SLNB (22.0±7.0 ml vs.73.5±39.6 ml; p<0.0001). Analysis by age group indicates a similar pattern of difference among the three groups. MSLNB and conventional SLNB have similar IR and FNR. Conclusion: As a minimally invasive technique, MSLNB can significantly reduce blood loss while providing similar IR and FNR, indicating that it can be a promising alternative to conventional SLNB. Conclusion: Variations in popliteal artery terminal branching pattern occurred in 7.4% to 17.6% of patients. Pre-surgical detection of these variations with MD CTA may help to reduce the risk of iatrogenic arterial injury by enabling a better surgical treatment plan.

Słowa kluczowe

EN

Breast cancer; sentinel lymph node; mastoscopy

• Czasopismo: Open Medicine
• Rocznik: 2014
• Tom: 10
• Numer: 1

Daty

otrzymano

2015-02-17

zaakceptowano

2015-09-14

online

2015-10-26

Twórcy

autor

Boni Ding

• Department of General Surgery, The
  Third Xiangya Hospital, Central South University, Changsha, Hunan,
  410013, China

autor

Hongyan Zhang

• Department of General Surgery, The
  Third Xiangya Hospital, Central South University, Changsha, Hunan,
  410013, China

autor

Xiaorong Li

• Department of General Surgery, The
  Third Xiangya Hospital, Central South University, Changsha, Hunan,
  410013, China

autor

Liyuan Qian

• Department of General Surgery, The
  Third Xiangya Hospital, Central South University, Changsha, Hunan,
  410013, China

autor

Xuedong Chen

• Department of General Surgery, The
  Third Xiangya Hospital, Central South University, Changsha, Hunan,
  410013, China

autor

Wei Wu

• Department of General Surgery, The
  Third Xiangya Hospital, Central South University, Changsha, Hunan,
  410013, China

autor

Yanguang Wen

• Department of General Surgery, The
  Third Xiangya Hospital, Central South University, Changsha, Hunan,
  410013, China

autor

Yujun Zhao

• Department of Transplantation
  Surgery, The Third Xiangya Hospital, Central South University, 138
  Tongzipo Rd, Hexiyuelu Dist., Changsha, Hunan 410013, China

Bibliografia

• [1] Ernst M.F., Voogd A.C., Balder W., Klinkenbijl J.H., and RoukemaJ.A., Early and late morbidity associated with axillary levels I-IIIdissection in breast cancer, J Surg Oncol, 2002, 79, 151-155;discussion 156[Crossref]
• [2] Hack T.F., Cohen L., Katz J., Robson L.S., and Goss P., Physicaland psychological morbidity after axillary lymph nodedissection for breast cancer, J Clin Oncol, 1999, 17, 143-149[Crossref]
• [3] Lyman G.H., Giuliano A.E., Somerfield M.R., Benson A.B., 3rd,Bodurka D.C., Burstein H.J., et al., American Society of ClinicalOncology guideline recommendations for sentinel lymph nodebiopsy in early-stage breast cancer, J Clin Oncol, 2005, 23,7703-7720[Crossref]
• [4] Giuliano A.E., McCall L., Beitsch P., Whitworth P.W.,Blumencranz P., Leitch A.M., et al., Locoregional recurrenceafter sentinel lymph node dissection with or without axillarydissection in patients with sentinel lymph node metastases:the American College of Surgeons Oncology Group Z0011randomized trial, Ann Surg, 2010, 252, 426-432; discussion432-423
• [5] Giuliano A.E., Hunt K.K., Ballman K.V., Beitsch P.D., WhitworthP.W., Blumencranz P.W., et al., Axillary dissection vs no axillarydissection in women with invasive breast cancer and sentinelnode metastasis: a randomized clinical trial, JAMA, 2011, 305,569-575[WoS]
• [6] Veronesi U., Viale G., Paganelli G., Zurrida S., Luini A.,Galimberti V., et al., Sentinel lymph node biopsy in breastcancer: ten-year results of a randomized controlled study, AnnSurg, 2010, 251, 595-600[WoS]
• [7] Belmonte R., Garin O., Segura M., Pont A., Escalada F., andFerrer M., Quality-of-life impact of sentinel lymph nodebiopsy versus axillary lymph node dissection in breast cancerpatients, Value Health, 2012, 15, 907-915[Crossref]
• [8] Krag D.N., Anderson S.J., Julian T.B., Brown A.M., Harlow S.P.,Ashikaga T., et al., Technical outcomes of sentinel-lymph-noderesection and conventional axillary-lymph-node dissection inpatients with clinically node-negative breast cancer: resultsfrom the NSABP B-32 randomised phase III trial, Lancet Oncol,2007, 8, 881-888[WoS][Crossref]
• [9] Luo C., Guo W., Yang J., Sun Q., Wei W., Wu S., et al.,Comparison of mastoscopic and conventional axillary lymphnode dissection in breast cancer: long-term results froma randomized, multicenter trial, Mayo Clin Proc, 2012, 87,1153-1161[WoS][Crossref]
• [10] Lee E.-K., Park Y.-L., and Pae W.-K., [Endoscopic Sentinel NodeBiopsy], Journal of Breast Cancer, 2003, 6, 174-179
• [11] Woo H.-D., Han S.-W., Son D.-M., Kim S.-Y., Lim C.-W., and LeeM.-H., [Endoscopic sentinel lymph node biopsy in breast cancersurgery: feasibility and accuracy of the combined radioisotopeand blue dye], Journal of Breast Cancer, 2010, 13, 59-64[WoS][Crossref]
• [12] Cody H.S., 3rd and Borgen P.I., State-of-the-art approaches tosentinel node biopsy for breast cancer: study design, patientselection, technique, and quality control at Memorial Sloan-Kettering Cancer Center, Surg Oncol, 1999, 8, 85-91[Crossref]
• [13] Brown L.D., Cai T., and DasGupta A., Interval estimation for abinomial proportion, Statistical Science, 2001, 16, 101-198
• [14] Edwards D. and Berry J.J., The efficiency of simulation-basedmultiple comparisons, Biometrics, 1987, 43, 913-928[Crossref]
• [15] Cody H.S., 3rd, Sentinel lymph node mapping in breast cancer,Breast Cancer, 1999, 6, 13-22[Crossref]
• [16] Miltenburg D.M., Miller C., Karamlou T.B., and Brunicardi F.C.,Meta-analysis of sentinel lymph node biopsy in breast cancer, JSurg Res, 1999, 84, 138-142[Crossref]
• [17] National Bureau of Statistics of the People’s Republic of China.Good and steady development of the national economy ofChina in 2013. 2014 [cited 2014 01/23/2014]; Available from:http://www.stats.gov.cn/tjsj/zxfb/201401/t20140120_502082.html.
• [18] Kootstra J., Hoekstra-Weebers J.E., Rietman H., de Vries J., BaasP., Geertzen J.H., et al., Quality of life after sentinel lymph nodebiopsy or axillary lymph node dissection in stage I/II breastcancer patients: a prospective longitudinal study, Ann SurgOncol, 2008, 15, 2533-2541[Crossref]
• [19] Zhang H., Li X., Xiang K., Hu G., and Ding B., [Value of lipolyticsolution injection in axillary lymph node dissection for breastcancer], Chinese Journal of General Surgery, 2013, 22, 551-554
• [20] Mu W., Li Y., Tong X., Yang Q., and Song F., [The hemostaticeffect of preincisional subcutaneous drug injection in breastcancer], Chinese Journal of General Surgery, 2012, 21, 627-630
• [21] Yamashita K. and Haga S., 3D-CT mammary lymphography forsentinel node biopsy, Nihon Rinsho, 2012, 70 Suppl 7, 377-380

Identyfikatory

DOI

10.1515/med-2015-0057